ANXA1 in breast cancer prognosis
ANXA1-positive breast tumors clustered with poor-prognosis features (high grade, basal/TN, BRCA1/2) and worse outcomes in some high-risk subgroups such as HER2+.
Source
Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis
Study at a glance
- Design
- Cohort — Pooled BCAC tumour series plus familial BRCA cases; ANXA1 IHC associations
- N
- N=5752 · BCAC patients in primary analyses; plus familial BRCA cases in secondary analyses
- Population
- Women with breast cancer in pooled BCAC cohorts (mostly non-BRCA carriers)
- Outcome
- ANXA1 associations with tumour subtype markers and breast-cancer-specific survival
Structured fields used in claim comparison tables when every cited study has a complete layer.
Inspect source passages
ANXA1 in breast cancer prognosis
These passages occur verbatim in the stored paper text. They support the points listed below; they do not verify every statement in the explanation.
Conclusion on phenotype?
ANXA1 expression is associated with tumors with selected well-known poor prognosis characteristics (e.g. poor differentiation grade, triple negative, BRCA1/2 mutations).
Authors’ caution?
Further studies are needed to elucidate whether ANXA1 is indeed a prognostic factor or may be used to predict chemotherapy response.
What they did
Pooled BCAC tumor series (5,752 patients plus familial BRCA cases) assessed ANXA1 expression associations with subtype markers and breast-cancer survival.
What they found
High-grade tumors had higher ANXA1 odds (OR adj 1.59); ANXA1 linked to basal-like/TN features; HER2+ ANXA1-overexpressing cases had worse 10-year BCSS (HR adj 1.70).
The limits
What it doesn't show
Does not prove ANXA1 is a ready clinical assay or establish chemotherapy predictive use without further trials.
Key terms
- ANXA1
- Annexin A1 protein assayed in tumor tissue.
- BCAC
- Breast Cancer Association Consortium pooled cohorts.
- Triple negative
- ER/PR/HER2-negative tumors enriched for ANXA1 positivity.
- BCSS
- Breast cancer-specific survival.
- HER2+
- HER2-overexpressing subtype where ANXA1 related to worse outcome.
- Basal-like markers
- EGFR and/or CK5/6 positivity associated with ANXA1.
Flashcards
0 of 10 answers reviewed
Research intelligence for this paper
See its role on concept claims, tensions it is part of, placement history, and related discoveries.
Quiz yourself
BCAC N roughly?
Common questions
How many BCAC patients?
5,752 (plus 107 BRCA1/2 familial cases).
Grade association?
OR adj 1.59 for grade 2–3 ANXA1 positivity.
HER2+ survival?
10-year BCSS HR adj 1.70 with ANXA1 overexpression.
Bottom line?
ANXA1 marks aggressive biology; prognostic role needs further study.
More on Oncology outcomes